Convenia (cefovecin sodium) is the long-acting cephalosporin injection that changed how small-animal clinics treat skin infections: one subcutaneous shot replaces 10–14 days of oral pills an owner may or may not give. That convenience is real, and so is the reason a subset of owners and veterinarians worry about it. Because cefovecin persists in the body for roughly 65 days, an adverse reaction that begins after the injection cannot simply be "stopped" the way you would stop a daily pill.

To put concrete numbers on what veterinarians and owners actually report, VetMedGuide analyzed the FDA Center for Veterinary Medicine (CVM) public adverse-event database — the same system manufacturers and the public submit reports to. A public extract dated June 2026 contains 1.34 million animal adverse-event reports. We identified 8,334 reports naming cefovecin in dogs and cats, and tabulated their reactions, outcomes, species, and reporter type.

The headline: cefovecin reports are common, cat-heavy, and carry a high "serious" flag and a substantial death-outcome count. Read carefully, though — those two signals are heavily confounded by who gets this drug and why, and they do not establish that Convenia caused the outcome. That distinction is the whole story.

How we identified reports

FDA's public database masks brand names (every product is labeled "MSK"), so reports were matched on the active ingredient cefovecin. The 8,334-figure counts unique reports in dogs (2,792) and cats (5,542); 68 reports naming cefovecin in humans or exotic species were excluded. Each report is a spontaneous submission — from a veterinarian, an owner, or another source — and the FDA explicitly cautions that these reports cannot be used to estimate true event rates or to prove a product caused a reaction. A single sick animal can generate multiple reaction terms, so reaction counts are not additive to the report total.

Cats outnumber dogs roughly two to one

The cat skew reflects how Convenia is used in practice. In cats, an injectable antibiotic sidesteps the pilling battle entirely, and feline skin infections, wounds, and abscesses (often Pasteurella multocida) are core label indications. Median age across both species was 9.0 years and median weight was 5.1 kg — an older, smaller-patient population that already carries more comorbidity than the average clinic patient.

Only 23.5% of these reports listed cefovecin as the sole drug. The rest involved concomitant medications, which matters a great deal for interpretation (below).

The reactions veterinarians and owners report most

The GI and lethargy cluster — vomiting, diarrhea, anorexia, not eating — is exactly what the Convenia label lists as the most common side effects, and it mirrors what oral cephalosporins cause too. These are the reactions an owner should expect to hear about and that usually resolve with supportive care.

Two signals deserve more nuance: death/death-by-euthanasia and seizure.

The death-outcome number, read honestly

Across the 8,334 reports, 1,138 listed "Died" and 736 listed "Euthanized" as an outcome — about 22.5% of cefovecin reports carried a death outcome, and 49.7% carried a "serious" adverse-event flag. (These are structured-outcome counts; they differ slightly from the "Death" and "Death by euthanasia" reaction-term rows in the table above because outcomes and reactions are recorded in separate fields — a report can carry a fatal outcome without listing "death" as a coded reaction, and vice versa.) On the face of it that sounds alarming. It should not be read as a cefovecin mortality rate, for three reasons baked into how this drug is used:

1. Convenience bias in reporting. Severe and fatal outcomes are reported far more often than mild ones. An animal that vomits once and recovers rarely generates an FDA report; one that dies almost always does.
2. A sicker baseline population. The median age was 9 years, more than three quarters of reports involved concomitant drugs, and the indication is often an infected wound, abscess, or pyoderma in an animal already under veterinary care for something else. Underlying disease — not the injection — is frequently the driver of a poor outcome.
3. The long half-life creates an attribution trap. Because cefovecin lingers for weeks, any adverse event that occurs in that window can be filed against it, even when the true cause is the primary illness, concurrent drugs, or progression of disease.

The honest synthesis: the death-outcome count tells you that serious, sometimes fatal illness occurs in the population receiving Convenia and that these events get reported against the drug. It does not tell you that Convenia caused those deaths. The FDA's own label language, and Convenia's continued approval, reflect that distinction.

That said, the legitimate clinical concern is not mortality-rate arithmetic. It is that cefovecin cannot be removed once given. If a patient has a true hypersensitivity reaction — anaphylaxis, which the label notes has been reported — the drug will continue to circulate. That irreversibility is the real reason the "is it worth it?" conversation exists, and it is the reason Convenia is contraindicated in any animal with a known beta-lactam (penicillin or cephalosporin) allergy.

Neurologic signs: rare but present

Seizure appears in 540 reports and ataxia in 515. In context of 8,334 reports that is a small minority, and the European public assessment report classifies neurologic signs (ataxia, convulsion, seizure) with cefovecin as "very rare." The Convenia label's foreign-market experience section lists death, tremors/ataxia, seizures, anaphylaxis, acute pulmonary edema, facial edema, injection-site reactions (alopecia, scabs, necrosis, erythema), and hemolytic anemia as voluntarily reported. These are signals to know, not frequencies to fear.

A lack-of-efficacy signal worth noting

1,090 reports involved "lack of expected effectiveness" (alone or alongside a safety issue). Cefovecin's spectrum is narrow and skin-focused; the label calls for use based on identification and susceptibility testing of the target pathogen. When Convenia is chosen empirically for an infection outside its labeled spectrum — urinary, respiratory, or deep tissue — a subset of cases will fail. Cross-resistance with other beta-lactams and cephalosporins is documented. If a cat is not improving 5–7 days after the injection, that is the point to re-evaluate the diagnosis and culture, not to assume the injection "didn't take."

Reporting patterns over time

Cefovecin was first FDA-approved for dogs and cats in April 2008 (NADA 141-285). Reports in the public database climb from 2012 onward and run roughly 600–730 per year through 2025, with no dramatic spike. In June 2025 the FDA approved the first generic cefovecin sodium injection, so clinicians will increasingly see both brand and generic vials; the active ingredient, the long half-life, and the adverse-event profile are the same.

What to ask your veterinarian

Convenia is appropriate when an owner genuinely cannot administer oral medication, when the suspected pathogen is susceptible, and when the patient has no beta-lactam allergy. The questions that sharpen the decision:

• Is a beta-lactam allergy possible? If yes, Convenia is off the table.
• Is the infection within cefovecin's labeled spectrum? Skin, wounds, abscesses — yes. Suspected urinary or deep infection pushes toward culture-directed oral therapy instead.
• What do we do if there is no improvement in a week? Agree on a recheck window (typically 5–7 days) before the injection is given, so a non-responder is not left to wait out the 14-day window.
• What signs mean call the clinic immediately? Facial swelling, hives, trouble breathing, repeated vomiting, profound lethargy, or collapse — these warrant same-day evaluation for a hypersensitivity reaction.

Because the drug clears slowly, owners who notice any of these signs in the weeks after an injection should contact the clinic rather than waiting it out. If you suspect a reaction, ask your veterinarian to file an adverse drug event report with the manufacturer and the FDA — that reporting is what populates the database analyses like this one rely on.

Sources

• FDA CVM, animal adverse-event database (public extract, June 2026); analysis by VetMedGuide. The FDA cautions that spontaneous reports do not establish causation or true event rates. https://www.fda.gov/animal-veterinary/safety-health/reporting-animal-drug-and-device-side-effects-and-product-problems
• Convenia (cefovecin sodium) prescribing information, DailyMed (post-approval adverse events, contraindications, foreign-market experience, 65-day clearance). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2daeaf25-f98f-49d3-943c-f604a844d93c
• FDA, "FDA approves first generic cefovecin sodium injection for treating skin infections in dogs and cats" (June 24, 2025; original Convenia approval April 25, 2008, NADA 141-285). https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-cefovecin-sodium-injection-treating-skin-infections-dogs-and-cats
• FOI Summary, NADA 141-285 (Convenia original approval; field-study adverse reactions in dogs and cats). https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/849
• European Medicines Agency / EU public assessment report, cefovecin (neurologic signs classified "very rare"; cross-resistance with beta-lactams). https://ec.europa.eu/health/documents/community-register/2024/20240530162584/anx_162584_en.pdf